Drug Trial Radar · NCT02609776
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
751
Actual
Start
May 24, 2016
Primary completion
Dec 31, 2026
Study completion Dec 31, 2027
Sponsor
- Lead sponsor
- Janssen Research & Development, LLCJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Nov 20, 2015
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of study is to evaluate the safety, pharmacokinetics, and preliminary efficacy of Amivantamab as a monotherapy and in combination with lazertinib, and to determine the recommended Phase 2 dose (RP2D) (monotherapy), recommended Phase 2 combination dose (RP2CD) (combination therapy), and to determine recommended Phase 2 Dose (RP2q3W) with combination chemotherapy (Amivantamab in combination with standard of care carboplatin and pemetrexed) in 21 day treatment cycle for participants with advanced non-small cell lung cancer (NSCLC).
Conditions
- Non-Small-Cell Lung Cancer
Interventions
AmivantamabDrug
The first cohort of participants will receive IV infusions of Amivantamab 140 mg as monotherapy. Each subsequent cohort will receive IV infusions of Amivantamab at increased dose level until maximum tolerated dose is reached or all planned doses are administered. Participants will receive lazertinib and Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. The duration of each treatment cycle is 28 days. In Chemotherapy Combination Cohort, participants will receive Amivantamab, administered on a 21-day cycle, in combination with the administration of standard of care carboplatin and pemetrexed.
AmivantamabDrug
Participants will receive IV infusion of Amivantamab as monotherapy at RP2D regimen or in combination lazertinib at RP2CD regimen as determined in Part 1.
LazertinibDrug
Lazertinib will be administered in combination with Amivantamab at predefined dose levels, based upon observed safety and protocol defined criteria. Lazertinib will be administered daily on the 28-day Amivantamab treatment cycle.
CarboplatinDrug
Participants will receive carboplatin in combination with pemetrexed and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
PemetrexedDrug
Participants will receive pemetrexed in combination with carboplatin and Amivantamab as an IV infusion on 21-day treatment cycle in Part 1 Chemotherapy Combination Cohort only.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants With Dose Limiting Toxicity (DLT)Time frame: Up to Day 28
- Part 2: Number of Participants With Adverse Events (AEs) and Serious AEsTime frame: Screening up to follow-up (30 [+7] days after the last dose)
- Part 2: Overall Response Rate (ORR)Time frame: Up to End of Treatment Follow (EOT) Up Period (30 [+7] days after the last dose)
- Part 2: Duration of Response (DOR)Time frame: Up to EOT Follow Up Period (30 [+7] days after the last dose)
- Part 2: Percentage of Participants With Clinical BenefitTime frame: Up to EOT Follow Up Period (30 [+7] days after the last dose)
- Trough Serum Concentration (Ctrough) of AmivantamabTime frame: Up to EOT (30 days after last dose)
- Area Under the Curve From Time Zero to End of Dosing Interval (AUCtau) of AmivantamabTime frame: Up to EOT (30 days after last dose)
Locations
69 sites in 10 countries. Site status is shown where the registry gives one.
Site not named
Duarte, California
Site not named
La Jolla, California
Site not named
Orange, California
Site not named
Santa Monica, California
Site not named
West Hollywood, California
Site not named
Tampa, Florida
Site not named
Chicago, Illinois
Site not named
Bethesda, Maryland
Site not named
Boston, Massachusetts
Site not named
Detroit, Michigan
Site not named
Rochester, Minnesota
Site not named
St Louis, Missouri
Site not named
New York, New York
Site not named
Portland, Oregon
Site not named
Philadelphia, Pennsylvania
Site not named
Houston, Texas
Site not named
Fairfax, Virginia
Site not named
Camperdown, Australia
Site not named
Heidelberg, Australia
Site not named
Kogarah, Australia
Site not named
Murdoch, Australia
Site not named
Woolloongabba, Australia
Site not named
Toronto, Ontario, Canada
Site not named
Beijing, China
Site not named
Changchun, China
Site not named
Changsha, China
Site not named
Chengdu, China
Site not named
Chongqing, China
Site not named
Guangong Apt/Yuncheng, China
Site not named
Hangzhou, China
Site not named
Hefei, China
Site not named
Nanchang, China
Site not named
Nanjing, China
Site not named
Wuhan, China
Site not named
Zhengzhou, China
Site not named
Bordeaux, France
Site not named
Dijon, France
Site not named
Lyon, France
Site not named
Marseille, France
Site not named
Paris, France
Showing 40 of 69 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.